Tags : Primary Immunodeficiencies

Grifols’ Xembify (20% SC Immunoglobulin) Receives FDA’s Approval for the

Shots: The approval of Xembify reflects Grifols’ commitment to R+D+i and innovation which enables the company to develop new therapies and enhances its Bioscience Division’s product portfolio Grifol is working with regulatory authorities to seek approval in Canada, Europe and other global markets and plans to launch the Xembify in the US in Q4’19 Xembify is […]Read More